Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;40(8):3291-3303.
doi: 10.1007/s12325-023-02551-9. Epub 2023 Jun 16.

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

Ola Landgren  1 , Omar Nadeem  2
Affiliations

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

Ola Landgren et al. Adv Ther. 2023 Aug.

Abstract

The introduction of novel immunotherapies has transformed the treatment landscape in multiple myeloma (MM). The addition of these agents has significantly improved patient outcomes; however, MM remains largely incurable, with heavily pretreated patients suffering from shorter survival times. To address this unmet need, the focus has shifted toward novel mode of action therapies, such as bispecific antibodies (BsAb), which simultaneously bind to immune effector cells and myeloma cells. Currently, there are several T cell-redirecting BsAb being developed that target BCMA, GPRC5D, and FcRH5. These BsAb show impressive clinical activity for the relapsed/refractory population targeted and will likely become an essential part of MM treatment protocols in the future. In this podcast, the authors summarize and highlight some of the T cell-redirecting BsAb currently in development for the treatment of relapsed/refractory MM with a focus on the data reported at the oral session for BsAb at the American Society of Hematology's 2022 meeting from clinical phase 1 and 2 studies. The six presentations reported the latest safety and efficacy data for the BsAb: talquetamab, elranatamab, teclistamab, forimtamig, and alnuctamab.

Keywords: Bispecific antibodies; Clinical trial; Multiple myeloma; Podcast.

Plain language summary

Multiple myeloma is a type of bone marrow cancer. It affects a type of white blood cell known as a plasma cell. Although multiple myeloma cannot be cured with current therapies, it can often be controlled with treatment. In some people with multiple myeloma, the treatment does not work at all, or it works at first but the cancer comes back. This is known as refractory or relapsed multiple myeloma. New types of treatment are needed for these people.Researchers are studying a type of antibody made in a laboratory called a bispecific antibody. They are a new type of treatment for multiple myeloma that work in a different way to existing treatments. This means they may help people who earlier treatments did not work well for. Bispecific antibodies use the body’s immune system to kill cancer cells. They work by attaching to two different types of proteins: one found on plasma cells, and another on a type of white blood cell called a T cell.At the American Society of Hematology’s 2022 meeting, researchers presented results from clinical trials studying five different bispecific antibodies: talquetamab, elranatamab, teclistamab, forimtamig, and alnuctamab. In this podcast, two healthcare professionals summarize the most common side effects people had while taking these new medicines, and how manageable they were. They also discuss how effective these bispecific antibodies were at treating refractory or relapsed multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Ola Landgren: has received grant support from Leukemia & Lymphoma Society, Rising Tide Foundation, National Institutes of Health, Food and Drug Administration, Multiple Myeloma Research Foundation International Myeloma Foundation, Riney Family Foundation, Tow Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm Therapeutics; has received honoraria for scientific talks/participated in advisory boards for Adaptive, Amgen, Binding Site, Bristol Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by Takeda, Merck, Janssen, and Theradex. Omar Nadeem: has received grant support from Takeda and Janssen; has participated on advisory boards for Janssen, Bristol Myers Squibb, Karyopharm Therapeutics, Takeda, GSK, Adaptive Biotechnologies, GPCR Therapeutics, and Sanofi.

References

    1. Rodriguez-Otero P, San-Miguel JF. Cellular therapy for multiple myeloma: what's now and what's next. Hematol Am Soc Hematol Educ Progr. 2022;2022:180–189. doi: 10.1182/hematology.2022000396. - DOI - PMC - PubMed
    1. Cipkar C, Chen C, Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematol Am Soc Hematol Educ Progr. 2022;2022:163–172. doi: 10.1182/hematology.2022000334. - DOI - PMC - PubMed
    1. Kazandjian D, Kowalski A, Landgren O. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Leuk Lymphoma. 2022;63:3032–3043. doi: 10.1080/10428194.2022.2113532. - DOI - PMC - PubMed
    1. Chari A, Touzeau C, Schinke C, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results from MonumenTAL-1. Blood. 2022;140:384–387. doi: 10.1182/blood-2022-159707. - DOI
    1. Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140:388–390. doi: 10.1182/blood-2022-166494. - DOI - PubMed

Substances